Compare Howmet Aerospace Inc (HWM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Incyte Corporation — how do they compare? Howmet Aerospace Inc trades at $225.24 (market cap $88.76B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Howmet Aerospace Inc is far larger — about 3.9× Incyte Corporation's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Incyte Corporation for 33 Days on average.
| HWM | INCY | |
|---|---|---|
Market Cap | $88.76B | $22.85B |
Volume | 2,648,516 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $292.65 | $129.93 |
52-Week Low | $184.09 | $83.80 |
Typical Hold Time | 35 Days | 33 Days |
Enterprise Value | $92.86B | $18.35B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.24, up 1.14% with strong fundamental performance including three consecutive quarterly earnings beats. The stock shows bearish technical signals despite robust profitability metrics with 20.52% net income margin and 34.89% ROE. Recent news highlights defense aerospace strength and upcoming Q3 2026 earnings announcement on October 29, 2026.
Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 46% upside potential. Key risks include technical weakness, valuation multiples above industry averages, and dependence on aerospace sector recovery. The combination of strong fundamentals and analyst optimism suggests potential for recovery from current technical pressure.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
